Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-30), Pacific Biosciences of California's 3-1 Month Momentum % is 5.66%.
PACB's 3-1 Month Momentum % is ranked better than 87.75% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: -7.08
vs PACB: 5.66
Pacific Biosciences of California (NAS:PACB) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Pacific Biosciences of California 3-1 Month Momentum % Related Terms
PACB vs DCTH, CLPT, SI: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Pacific Biosciences of California's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Biosciences of California 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Pacific Biosciences of California's 3-1 Month Momentum % falls into.
Pacific Biosciences of California (NAS:PACB) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Biosciences of California (PACB) has a 3-1 Month Momentum % of 5.66% as of Jul. 30, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Pacific Biosciences of California and its competitors. According to the industry distribution chart, Pacific Biosciences of California ranks #104 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 12.2%.
Is Pacific Biosciences of California's 3-1 Month Momentum % too high?
Pacific Biosciences of California's current 3-1 Month Momentum % is 5.66%. Based on the distribution chart, Pacific Biosciences of California ranks #104 out of 849 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Pacific Biosciences of California has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's 3-1 Month Momentum % compare to DCTH and CLPT?
According to the Medical Devices & Instruments industry distribution chart, Pacific Biosciences of California ranks #104 out of 849 companies for 3-1 Month Momentum %. This places Pacific Biosciences of California in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current 3-1 Month Momentum % is 5.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (PACB) is currently considered Fairly Valued. The stock's GF Value™ is $1.62, compared to a current price of $1.47 — trading 9.3% below its estimated fair value. The current 3-1 Month Momentum % is 5.66%. Pacific Biosciences of California's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Pacific Biosciences of California (PACB), the current 3-1 Month Momentum % is 5.66% as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Biosciences of California (PACB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued.
The current stock price of $1.47 is trading 9.3% below its estimated GF Value™ of $1.62.
GuruFocus considers Pacific Biosciences of California to be Fairly Valued.
Key valuation signals for PACB:
3-1 Month Momentum %: 5.66%
GF Value™: $1.62 vs. price of $1.47 (9.3% below fair value)
No single metric tells the full story. See the PACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Biosciences of California Business Description
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
55GF Score
Get the complete analysis for PACB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PACB has been successfully added to your 
